Autoimmune diseases (ADs) encompass multisystem disorders, and cardiovascular involvement is a well-known feature of autoimmune and inflammatory rheumatic conditions. Unfortunately, subclinical and early cardiovascular involvement remains clinically silent and often undetected, despite its well-documented impact on patient management and prognostication with an even more significant effect on severe and future MACE events as the disease progresses. Cardiac magnetic resonance imaging (MRI), today, commands a unique position of supremacy versus its competition in cardiac assessment and is the gold standard for the non-invasive evaluation of cardiac function, structure, morphology, tissue characterization, and flow with the capability of evaluating biventricular function; myocardium for edema, ischemia, fibrosis, infarction; valves for thickening, large masses; pericardial inflammation, pericardial effusions, and tamponade; cardiac cavities for thrombosis; conduction related abnormalities and features of microvascular and large vessel involvement. As precise and early detection of cardiovascular involvement plays a critical role in improving the outcome of rheumatic and autoimmune conditions, our review aims to highlight the evolving role of CMR in systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), rheumatoid arthritis (RA), systemic sclerosis (SSc), limited sclerosis (LSc), adult-onset Still's disease (AOSD), polymyositis (PM), dermatomyositis (DM), eosinophilic granulomatosis with polyangiitis (EGPA) (formerly Churg-Strauss syndrome), and DRESS syndrome (DS). It draws attention to the need for concerted, systematic global interdisciplinary research to improve future outcomes in autoimmune-related rheumatic conditions with multiorgan, multisystem, and cardiovascular involvement.

Keywords: autoimmune disease, cardiac MRI, fibrosis, late gadolinium enhancement, thrombosis, antiphospholipid, lupus, rheumatoid arthritis
INTRODUCTION

Rheumatologists know cardiac involvement among diseases within the spectrum of autoimmunities, such as systemic lupus erythematosus (SLE) or antiphospholipid syndrome (APS). However, other less frequent conditions seen in their daily practice may impact the heart, which is rarely recognized during the subclinical period.

Autoimmune disease (AD) comprises a broad spectrum that affects many levels and structures of the cardiovascular (CV) system. However, some of them, such as the different vasculitides and the spondyloarthropathies, are too extensive to be part of a generic revision since each could be a complete chapter. Therefore, to decide what diseases are included in this review, we conducted a literature search, as shown in the following algorithm that describes the broad spectrum of this group of pathologies beyond the scope of this review.

Different non-invasive CV imaging modalities play an essential role in diagnosing the involvement of the heart in these diseases; however, their diagnostic accuracy varies depending on their pretest probability, the type and severity of involvement, and the local expertise. Therefore, such involvement is not always detected during their early phases (Table 1). Cardiovascular magnetic resonance (CMR) is an imaging modality that could have a relevant role in ADs. However, it is not well recognized and with limited widespread due to different reasons described in this review in more detail.

CMR TECHNIQUE

This non-invasive imaging modality is considered the gold standard for many quantitative measurements of cardiovascular disease. Moreover, extensive scientific evidence supports a useful diagnostic tool for different pathologies such as ischemic cardiomyopathy (ischemia and viability), diverse non-ischemic cardiomyopathies, myocarditis, right ventricular disease, and congenital heart disease (1). Up to date, there are constantly updated standards, consensus, and clinical indications (2), which is slowly gaining more and more class I indications in European and American Guidelines (3–20) and position statements (21–26). Currently, the are standard data acquisition (27), guides on how to interpret (28) and structure a comprehensive report (2), and which allows extracting the most information from a CMR scan to maintain its high reproducibility and to feed international registries and databases to gain more clinical indications based on evidence are constantly updating during the past two decades by the Society for Cardiovascular Magnetic Resonance (SCMR).

Unfortunately, nowadays, many referring physicians have little or no training in this technique, provoking an unintended lack of knowledge of CMR general principles, terminology (1), and clinical indications; which allows the global misconception of the recognized cons of the technique to become more robust and sometimes even a myth that limits its proper application on the benefit of the patients.

The SCMR recognizes that several reasons exist for this problem which increases the complexity of selecting appropriate testing for a given clinical situation, such as the complex underlying physics and terminology that are not intuitively understood by the referring physician or non-CMR-expert, along with multiple and even vendor-specific terms uses for the same technique. To help the referring physicians and the non-CMR-expert users, a simplified CMR terminology was officially launched in 2014 by the Society to be used in clinically oriented publications to improve the acceptance and widespread use of CMR in clinical routine (1).

For a general CMR, the study used in clinical routine, the sequences (type of image) are “black-blood CMR” used to study cardiac structure and morphology; by adding a specific fat saturation, the technique is possible to obtain an “edema CMR” image that is extremely useful to determine the presence and location of water (edema) within the myocardium and to delineate the pericardium in cases where it is thicker than normal. If using a specific type of black-blood CMR sequence is also possible to obtain the “iron CMR,” which allows for identifying and quantifying the iron in the heart. For functional analysis, such as all echocardiographic measurements and projections, CMR has the sequences generally called “cine CMR,” which are high-resolution electrophysiology (ECG) gated images with high endocardial border definition, allowing the analysis of cardiac function during the cardiac cycle. These cine sequences are the gold standard for analyzing left and right ventricular functions for which other imaging modalities are compared and validated (29, 30). To these “cine CMR” sequences, it is possible to add the strain techniques by using post-processing tools commercially available, as in echocardiography (Echo) which allows for analyzing the ventricular mechanics. Using a specific sequence in 2D or 4D, we can obtain the “flow CMR” with 2D flow CMR can get the same information as Echo using Doppler techniques. For more complex anatomy, single acquisition with multiples analysis, without the limitation of patient cooperation currently 4D flow CMR emerged as a valuable option, allowing even the wall stress shear analysis that is fundamental in arterial wall diseases (31).

With the administration of intravenous contrast media, which is a paramagnetic agent (gadolinium), currently approved to be used even in patients with renal dysfunction without the risk of systemic nephrogenic fibrosis development (32), it is possible to obtain the “perfusion CMR” by analyzing the first pass of the contrast material into the vascular system first into the cardiac chambers and then into the myocardium allowing the identification and quantification of normal and abnormal perfusion in areas of myocardial ischemia or necrosis. The intravenous administration of the contrast media can be used to obtain a high-resolution magnetic resonance angiography from the supra-aortic vessels down to the aortic bifurcation within the same cardiac MRI study. By waiting 7–10 mins after gadolinium administration, when other images can be obtained, the “late gadolinium enhancement (LGE) CMR” images are broadly recognized ones showing myocardial necrosis and fibrosis. Recently, the addition of mapping techniques during this same scan time acquisition, the T1 and T2 mapping with the process of the extracellular volume map allows the identification of the diffuse process of inflammation, edema, and fibrosis; which is essential for...
the ADs mainly in early stages before becoming clinically evident (1).

Since up-to-date CMR is not included in the Clinical Guidelines for evaluating ADs with CV involvement, the following case description will serve as the preamble for the rest of the manuscript.

A young woman, 34 years old, was recently diagnosed with RA and suddenly started with signs and symptoms of heart failure (HF), which was reviewed by her Rheumatologist, who considered that she would need to see a Cardiologist. During her consultation with an expert cardiologist, she was diagnosed using ECG, laboratory tests, and Echo as having mild left ventricular dysfunction with moderate pericardial effusion with no constrictive physiology; and she was started on proper maximum medical treatment for this condition. However, after two weeks of no improvement and being re-evaluated by her Rheumatologist, she was asked to take a second cardiology opinion with a cardiologist expert in ADs and advanced cardiovascular imaging. After being evaluated by the second cardiologist and using only the same information she had for her first cardiologist, she was recommended for an oriented autoimmune cardiac MRI protocol, where she was identified as having a normal left ventricular function, moderate pericardial effusion, unresponsive to the standard treatment and additional three key findings, the presence of amyloidosis probable secondary and related to the RA, an inflammatory component

TABLE 1 | CMR value and Pros and Cons compared with other imaging modalities.

| Underlying mechanism of the disease | ECG | Chest X-ray | CT scan | Echo | CMR | Nuclear (SPECT/PET) |
|-------------------------------------|-----|-------------|---------|------|-----|------------------|
| VHD-Libman-Sacks endocarditis       | No  | No          | Yes, if large | Yes | Yes | PET, yes, if large |
| Pericardial effusion                | No — just a very large one | Yes | Yes | Yes | CT aspect of PET, if large |
| Pericarditis — inflammation         | Severe ones | No | No | No | Yes | PET, if severe |
| Noncalcified constrictive physiology of the pericardium | No | No | No | Yes | Yes |
| RV dysfunction                      | Late | Late | Late | Yes, but not always | Yes | No |
| LV dysfunction                      | Late | Late | Late | Not subclinical | Yes | Late |
| Myocardial edema                    | No  | No | No | No | Yes | No |
| Myocardial ischemia                 | Yes | No | No | Yes, indirectly | Yes | Yes |
| Myocardial infarction               | No smaller ones | No | No | Yes, not small or subendocardial | Yes | Yes, but not small or subendocardial |
| Myocarditis                         | No  | No | No | No, just large ones | Yes | SPECT — No* PET—Yes |
| Coronary artery disease             | Yes | No | No—CCTA | Not directly | Yes | Not directly |
| Microvascular dysfunction           | Yes | No | No | No | Yes | Only PET |
| Aortic involvement                  | No  | Large ones | No, in subclinical cases | Aortic root, no in subclinical cases | Yes | No |
| Pulmonary arteries                  | No  | Late | Yes—CTA till distal branching | Main trunk and branches | Yes—till proximal branching | No |
| Pulmonary hypertension              | Late | Late | Late | Yes | Yes | No |
| Radiation free                      | Yes | No | No | No | Yes | No |
| Availability                        | ++ ++ | ++ ++ | ++ + | ++ ++ | ++ | ++ |
| Costs                               | + | + | ++ | ++ | ++++/+++ | ++/+/+/+ |
| Claustrophobia                      | No  | No | Yes—very rare | No | Yes | Yes—rare |
| Renal function contraindication     | No | No | Yes | No | No** | No |
| Implantable (metal) devices contraindication | No | No | No | No | No** | No |
| Recommended for routine use in younger people than 65 years old, mainly women — radiation risk | Yes | Yes | No | Yes | Yes | No |
| Reproducibility                     | Yes | Yes | Yes | No-operator dependent | Yes | Yes |
| Prognostic information              | No  | No | No | Yes | Yes | Yes |

*SPECT had the technique of Gallium-67, currently obsolete due to inherited limitations of the study; Tc⁹⁹m could be helpful in some cases.

**Currently, there are no absolute contraindications, contrast media could be used in renal impairment, and MRI scanning is possible with implantable devices. See dedicated literature for details and specifications.
of the pericardial disease and the involvement of valvular and vascular structures. As a result, her Rheumatologist modified the medical treatment to a more aggressive immunomodulatory agent with an excellent immediate response (33).

This case nicely illustrates and explains the motivation of the title and the purpose of this manuscript to review the pathophysiology of cardiac involvement and the cardiovascular magnetic resonance (CMR) findings of ADs.

There are many different diseases in the field of Rheumatology, including those considered systemic or localized with autoantibodies, those secondary to hypersensitivity, and others with unknown etiology with or without autoantibodies that involve spondyloarthropathies and vasculitides (34) those of genetic origin and some other miscellaneous as are shown in the algorithm of Figure 1.

Based on the literature research and the algorithm, we decided to include in this review the diseases that are of autoimmune origin with systemic presentation and known CV involvement and high prevalence, such as systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), rheumatoid arthritis (RA), systemic sclerosis (SSc), polymyositis (PM), dermatomyositis (DM); one disease from the group of spondyloarthropathies, the adult-onset Still’s disease (AOSD), one disease from the group of vasculitides, the eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome) (EGPA), granuloma cutis with polyangiitis (Wegener’s); SVV, small vessel vasculitis; CV, cryoglobulinemic vasculitis; IgAV, IgA vasculitis (Henoch-Schönlein); HUV, hypocomplementemic urticarial vasculitis (anti-C1q vasculitis); CS, Cogan’s syndrome; BS, Behcet’s syndrome.

### Diseases in Rheumatology

#### Systemic
- SLE
- APS
- SSc
- Dermatomyositis
- Polymyositis
- Sjogren’s syndrome
- RA

#### Localized
- Type I DM
- Hashimoto’s thyroiditis
- Myasthenia gravis

#### Secondary to Hypersensitivity
- Spondylitis
- Ankylosing spondylitis
- Reactive arthritis
- Psoriatic arthritis
- Inflammatory bowel disease arthritis
- Juvenile chronic arthritis
- Undifferentiated spondyloarthritides
- Still’s disease
- Hypertrophic osteoarthritis

#### Of Unknown Etiology
- Large vessel:
  - TA
  - Temporal arteritis
- Medium vessel:
  - PAN
- Small vessel:
  - ANCA AAV
  - GPA
  - Immune complex SVV
  - Goodpasture syndrome
  - CV
  - IgAV
  - HUV
- Variable vessel vasculitides:
  - CS
  - BS
- Single-organ vasculitides:
  - Cutaneous leukocytoclastic angitis
  - Cutaneous arteritis
  - Primary central nervous system vasculitis
  - Isolated aortitis
  - Others (idiopathic, Pauci-immune pulmonary capillaritis)

#### Secondary vasculitides:
- Associated with systemic disease:
  - SLE
  - RA
  - Sarcoid
  - Others (Sneddon syndrome)
- Associated with probable etiology:
  - Hepatitis C virus
  - Hepatitis B virus
  - Syphilis
  - Drug-associated immune complex
  - Drug-associated ANCA-associated
  - Cancer
  - Others (coronary artery vasculitis)

| Genetic | Other |
|---------|-------|
| Marfan
| Loeys-Dietz |
| Beals Hereditary
| Shprintzen-Goldberg |
| Weil-Marchesani
| Streaker |
| Marshall
| Engelmann-Commissural |
| Ehlers-Danlos
| Digenicphysical |
| Osteoarthropathies |
| MASS syndrome |
| Metabolic |
| Glucagon storage disease |
| Occult neoplastic |
| Infectious |
| Hematologic |
Systemic Lupus Erythematosus

General Description

Since 1924, when Libman and Sacks first published the association of aseptic vegetations and SLE (35), we have known specific manifestations involving the CV system in the context of ADs. CV involvement in SLE occurs at pericardial, valvular, and myocardial levels (Figures 2A,B). CVD is the leading cause of death in SLE patients (36–39). It is estimated that SLE patients have a two-fold risk of developing MI or stroke compared to the general population (38). Premenopausal women with SLE have a 50-fold more risk of MI than healthy matched controls (40, 41).

Recently, the 2019 update of the EULAR recommendations (42) for the management of SLE state that patients should undergo regular assessment for traditional and disease-related risk factors for CVD, including persistently active disease, increased disease duration, medium/high titers of antiphospholipid antibodies, renal involvement, and chronic use of glucocorticoids; and based on the CV risk profile patients may be candidates for low dose aspirin or lipid-lowering therapies (42). Unfortunately, classic risk scores for evaluating CVD can underestimate risk in SLE patients since they are primarily young women (43). In this matter, Petri et al. developed a formula to evaluate CV risk in SLE patients based on disease-related risk factors (44). Elevated CV risk in SLE patients at younger ages, particularly with disease-related risk factors, can prompt an evaluation of CVD risk in this population.

Clinical Manifestations of CV Involvement and Pathogenesis of Cardiac Manifestations

The most common CV manifestation is pericarditis presenting with pericardial effusion, which can occur in 11–54% of cases (39) during the disease (Figure 2A.a.1,2,2B.a.1–4,c.1–3). Even though it is the most common CV manifestation, cardiac tamponade rarely develops. It is associated with positive antinuclear antibodies (ANA), fever, and chest pain, just as acute viral pericarditis, so excluding other causes of pericardial disease in these patients is mandatory. Still, in disease activity, pericarditis is rarely due to other etiologies (39).

Valvular heart disease in SLE involves more than Libman-Sacks endocarditis (Figure 2A.e.1). Valve thickening (Figure 2A.e.2) and valvular dysfunction (Figure 2A.e.3) can also occur (45). In a study, Vivero et al. included 211 patients with SLE. Of those, 53 had significant valvular involvement; however, they found no valve vegetations in any of these patients (46). In a meta-analysis by Hussain et al., they included 2556 SLE patients. The most commonly involved was the mitral valve, with mitral regurgitation being the most common valve disease. Other lesions were mitral stenosis, tricuspid regurgitation (Figure 2A.e.3), and aortic regurgitation (47). In the same study, the authors found that compared to control subjects, SLE patients had an increased risk of developing valve disease, the highest risk being valvular thickening (RR 6.99, CI 3.64–13.44) and valvular vegetations (RR 7.73, CI 3.09–19.3) (47). VHD has been linked to high titers of antiphospholipid antibodies (aPL) (48, 49).

Specific manifestations can cause HF in SLE, which has been reported with a prevalence of 1–10% in SLE (47, 50). MI and coronary artery disease (CAD) are the leading causes of CVD in these patients (Figure 2B), besides being significant risk factors for the development of HF (50). Treatment of SLE with disease modifier drugs such as corticosteroids or hydroxychloroquine is further associated with increased CV risk (35) related to dose-dependent cardiotoxicity and resultant manifestations of restrictive cardiomyopathy (51). Dhakal et al. described risk factors associated with HF development in SLE. Traditional risk factors such as smoking, obesity, hypertension, CAD, advanced age, and male sex play a role in HF development, but also there are disease-specific risk factors such as left ventricular hypertrophy, described in as much as 20% of cases, myocarditis, chronic kidney disease, and vasculitis, among others (50). Primary myocardial involvement manifested as myocarditis affects ~3–9% of SLE patients (Figure 2A.b.d.1–5,f), while African-Americans are at higher risk (39).

Regarding the pathophysiology of CV manifestations in SLE, there is a role of immune complexes in CV manifestations of SLE. In pericarditis, for example, granular depositions of immunoglobulins and C3 complement have been found in pericardial tissue, and neutrophil predominance in pericardial fluid exudate, ANA (Figure 2B.g.1,2), and other autoantibodies can be found (39).

Even though autoimmunity is the hallmark of the disease, and immune complexes are presumed to be related to the CV manifestations of SLE, the exact pathophysiology behind them is still only somewhat understood (52).

Endothelial dysfunction (Figure 2A.c) is accepted as the central hypothesis of CVD, especially CAD, in SLE patients. The mechanism by which this occurs is complex. Roughly, endothelial dysfunction is caused by several pathways, including expression of vascular cell adhesion molecules, which correlates with higher coronary artery calcium scores (53), activation of type I interferon and IFN-α, which inhibit ENOS expression at protein and mRNA levels which impair insulin-mediated nitric oxide production in endothelial cells (54). Cellular mediators for endothelial dysfunction involve low-density granulocytes which form neutrophil extracellular traps that promote vascular leakage and activate the β-catenin signaling pathway (38). Conversely, T cells play a proatherogenic role through their migration to the arterial wall (55). Mercurio et al. reported increased radial artery stiffness, increased aortic pulse pressure, and its correlation with some inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), but not with disease activity in 43 SLE patients. The authors concluded that inflammation is the primary determinant of CV complications in SLE (56).

MI is mainly due to coronary atherosclerosis, but it might be due to acute in situ coronary thrombosis when there is an association with aPL (57). Arterial thrombosis manifests...
FIGURE 2 | (A) CMR findings in SLE—(A) from an arrhythmic perspective. A panel figure demonstrates the array of findings from a comprehensive CMR study in SLE from an arrhythmic perspective. (A.a) Shows normal global and regional right and left ventricular functions in SSFP sequence still cine images in short-axis views at the mid-ventricular level in end-diastole (A.a.1) and end-systole (A.a.2) LVEF 66% and RVEF 63%. (A.b) T2-W STIR sequence in short-axis view projection at a mid-ventricular level demonstrating mildly increased signal intensity in the anterior, anteroseptal, and inferoseptal segments (arrow) with a myocardial/skeletal muscle ratio of 2.8 and (A.f) a color-coded T2 mapping (native T2 value of 48 ms) consistent with myocardial edema. (A.c) Stress CMR with FPP T1-W sequence with adenosine infusion at 140 mcg/kg/min over 6 minutes shows a subendocardial ring perfusion defect (arrowheads) consistent with subendocardial ischemia due to endothelial dysfunction and probably microvascular disease (no obstructive coronary artery disease in CCTA). (A.d.1) LGE PSIR sequence. (A.d.1–3) short-axis views at basal (A.d.1), mid (A.d.2) and apical (A.d.3) levels, and long-axis views in 4-chambers (A.d.4,6) and 3-chambers (A.d.5) projections. The arrows in these images show areas of focal fibrosis in the subepicardium in the inferior segments in (A.d.1–3) from the base to the apex. (A.d.4,5) shows areas of midventricular LGE in basal anteroseptal and inferoseptal segments (arrows) and subepicardial enhancement in mid and apical inferolateral segments (arrow). (A.d.6) A zoomed image of the 4-chambers view showing LGE suggestive of LA fibrosis (arrow). (A.h) A polygraphic trace of an EP study showing atrial fibrillation successfully ablated. (Continued)
as coronary thrombosis in 23% (58) (Figure 2B.d.1,2). It has been described that MI secondary to coronary in situ thrombosis can be the first manifestation of SLE and APS which can be complicated by catastrophic APS (57) (Figure 2B). Treatment for STEMI in these patients must be as stipulated in current guidelines.

In patients with lupus myocarditis, the typical findings on endomyocardial biopsy are mononuclear cell infiltration, perivascular inflammation, and cardiomyocyte necrosis with granular immunoglobulins and complement deposition, which support the role of immune complexes (50).

Although it is not the most common manifestation of SLE, serositis is one of the American College of Rheumatology (ACR) classification criteria to define the disease (59). Serositis can manifest as pleurisy (Figure 2A.g) with pleural effusion, which occurs in 15–34% (60), or as pericarditis with pericardial effusion, which is the most common CV manifestation and can occur in 11–54% of patients with SLE (39, 60), during the disease. A study of the Hopkins Lupus Cohort evaluated predictors of pleurisy and pericarditis among different populations. They found that African-American ethnicity, male gender, and serological markers such as ESR, Anti-DNA, and low C3/C4 were strong predictors for serositis in the form of pleurisy and/or pericarditis (60).

**CMR Role**

Autopsy studies in patients with SLE show cardiac involvement in up to 40% of patients, of which only 10% were clinically diagnosed (40). Even though echocardiography is the leading non-invasive imaging modality in the initial evaluation of CVD, it might not be the appropriate initial modality in SLE patients since it is not ideal for tissue characterization. Mavrogeni et al. analyzed patients referred to evaluate typical and atypical cardiac symptoms with normal Echo and connective tissue diseases. They found that 25.2% of these patients had myocardial fibrosis. When the percentage of LV mass with late gadolinium enhancement (LGE) exceeded 5%, they were at increased risk of future cardiac events (61). Burkard et al. evaluated 30 SLE patients, mainly female, with no history of CAD and found that 43% (n = 13) had abnormal CMR; the main findings were the presence of LGE (Figure 2A.d.1–5, B.c.1–3), stress perfusion abnormalities (Figure 2A.c), and pericardial effusion (Figure 2B) (40). This reinforces the need for early CMR evaluation in these patients mainly for (1) detection of acute disease that cannot be diagnosed with Echo (e.g., arterial wall inflammation, asymptomatic myocardial involvement). (2) Evaluation of CAD with CMR perfusion techniques in patients with high CV risk-stratified with novel tools. (3) Evaluation of pericardial tissue. (4) Evaluation of valve involvement and (5) early initiation of cardiac protective treatment in patients with detected myocardial involvement, considered a risk factor for HF in these patients (62–64). See Table 2 for detailed CMR offerings to SLE and Table 1 for pros and cons over other imaging modalities.

**Antiphospholipid Syndrome**

**General Description**

Antiphospholipid antibody syndrome is characterized by thrombotic events, pregnancy-related comorbidities, or a series of non-thrombotic symptoms. Thrombotic events are arterial,
venous, and/or in the microvasculature. This syndrome could affect the brain, lungs, extremities, and the heart. It is called a catastrophic antiphospholipid syndrome, which involves multiple organs (65). An obstetric form is characterized by three or more consecutive spontaneous pregnancy losses at less than ten weeks of gestation, intrauterine growth restriction, and/or severe preeclampsia. However, other non-thrombotic presentations include valvular disease, livedo reticularis, kidney dysfunction, thrombocytopenia, hemolytic anemia, and cognitive dysfunction (66).

The antiphospholipid antibodies bind the beta-2-glycoprotein I, which is strongly linked to lipid surfaces and favors prothrombotic states by increasing cell adhesion of the E-selectin and tissue factor. It reduces the activity of the C-reactive protein, and the complement is activated. At platelets favors the expression of glycoprotein IIb/IIIa and the activation of neutrophils by generating NETosis and increasing the production of IL-8. Monocytes express higher levels of tissue factor. Recently, increased stimulation of the intracellular mTOR pathway involved in microvascular damage has been described (67).

Clinical Manifestations of CV Involvement and Pathogenesis of Cardiac Manifestations

The pathophysiological abnormalities in APS include vascular thrombosis of large and/or small venous and arterial systems (68). The cardiac involvement presents as valvular heart disease (VHD), intracardiac thrombosis, pulmonary hypertension (PH), right and/or left ventricular dysfunction (Figure 3a.1–2), ischemic heart disease due to involvement of the large epicardial coronary arteries or the microvascular circulation. Thrombosis is less frequent than the VHD but contributes to PH, microvascular (68), or even thrombosis of the epicardial coronary arteries.

It is well described that APS affects the heart valves in approximately 30% of the patients (68). Recently, the association of Libman-Sacks endocarditis with primary APS, and not only when associated with SLE, have been made and demonstrated that it is due to thrombosis and thickening of the valves with the formation of sterile fibro-fibrinous vegetations of the mitral and/or aortic valves on their endocardial surfaces (68–71) (Figure 3e.1–3).

The typical functional abnormality is non-hemodynamically significant mitral and aortic regurgitation, the most frequently affected mitral valve. This valvular involvement is reported as persistent or even progressive over time regardless of the anticoagulant or antplatelet therapy. Clinically, most patients remain asymptomatic for a long time, but eventually, they will require surgical treatment (68).

Intracardiac thrombosis is rarely reported (72); it produces masses in all four cavities (73–76), and even recurrent masses (77); usually adherent to the endocardial surface (74). These thrombotic masses mimic myxomas (73) or other tumors, even primary ones, by Echo (72). In addition to the presence of cardiac masses, the complication of frequent peripheral embolisms, particularly in the brain, is reported (72).

Many patients without the full criteria for APS or SLE have a stroke or this finding as to the initial manifestation, and since the initial diagnostic workup often does not include CMR; these patients end up at surgery without proper diagnosis and anticoagulation therapy until the histopathological result confirms the presence of thrombotic material suggesting the diagnosis (72–76). Additionally, the myocardial ischemia (see below) causes an ischemic subendocardium which in turn acts as a trigger for thrombus formation, especially if it coexists with left ventricular (LV) dysfunction (see below) (68).

PH is a rare but life-threatening condition in APS with or without SLE (78). The definition of PH is done by Echo based on estimated hemodynamic parameters (TTE) and has to be confirmed by right heart catheterization (RHC) (78). The underlying pathophysiological mechanism involves large vessel and microvascular thrombosis, recurrent pulmonary embolism, and endothelial remodeling (78–80). PH development in APS undergoes progressive worsening unless proper diagnosis and treatment, including anticoagulation, are established. A pulmonary endarterectomy is an option (11, 14), but it is a high-risk procedure with good results only in highly experienced centers (79–81), and it has an increased risk of thrombotic complications (78, 80, 81).

Right ventricular (RV) subclinical dysfunction is more prevalent in APS with or without SLE, and it negatively correlates with the serum levels of anticardiolipin antibodies (ACA) (82). The suggested mechanisms are the underlying inflammation
that produces subclinical vasculitis, myocarditis, or vascular stiffening, resulting in ventricular remodeling (83). Once PH has been established, RV dysfunction becomes clinical. However, it could also become life-threatening depending on its severity, the speed of installation, the proper diagnosis, treatment, and other comorbidities.

LV dysfunction is a rare presentation (84, 85) and the suspected mechanism identified in the autopsy is a widespread thrombosis of the intramyocardial arteries and arterioles (86, 87), which one can assume leads initially to microvascular dysfunction, then microinfarctions of the myocardium generating small scars and fibrosis and finally compromising the ventricular function. Myocardial edema (Figure 3b) has (88) also been described as catastrophic (89).

It is infrequent that APS patients develop dilated cardiomyopathy (90). However, a significant correlation exists between high titers of ACA IgM and HF (91).

Ischemic heart disease is generally caused by microvascular endothelial dysfunction (Figure 3c) with or without associated micro thrombosis (86) and minimal inflammation (92). Myocardial infarction (MI) is due to thrombosis or vasospasm (68) of the large epicardial coronary arteries. MI could be the first manifestation of the disease (93, 94).

### CMR Role

CMR has identified a high prevalence of myocardial scar (95), diffuse fibrosis (88) (Figure 3d.1–4), and endomyocardial fibrosis (96–98).

As mentioned before, APS can have many cardiovascular manifestations. Therefore, the “APS Task Force” has taken valvular heart disease related to APS as one of the “extra criteria” for its diagnosis (99). Even though echocardiography is usually the first non-invasive imaging technique for evaluating APS-related VHD, CMR has certain advantages, such as tissue

FIGURE 3 | CMR findings in APS. A figure demonstrates the array of findings from a comprehensive CMR study at a 1.5 Tesla scanner of APS. (a) SSFP sequence still cine images in short-axis view at the mid-ventricular level in end-diastole (a.1) and end-systole (a.2) show normal global and regional right and left ventricular functions, LVEF 63% and RV EF 56%. (b) T2-W STIR sequence in short-axis view at a mid-ventricular level shows mildly increased signal intensity in the anterior and antero-septal segments (arrow) with a myocardial/skeletal muscle ratio of 3.6 suggestive of myocardial edema. (c) Stress CMR with FFP T1-W sequence with adenosine infusion at 140 mcg/kg/min over 6 mins showing a subendocardial circumferential perfusion defect (arrowheads) consistent with subendocardial ischemia due to endothelial dysfunction and probably to a microvascular disease (no obstructive coronary artery disease demonstrated in ICA). (d) LGE PSIR sequence. (d.1–3) short-axis views at basal (d.1), mid (d.2), and apical (d.3) levels, and long-axis views in 4-chambers (d.4) and 3-chambers (d.5) projections. The arrows in these images demonstrate areas of focal fibrosis as mid-wall LGE in the anteroseptal segment in (d.1,d.2,d.4), and in the subepicardium of the inferior segment from the base to the apex. (d.5) Shows aortic root and ascending aorta dilatation confirmed by the CE-MRA in (g) and in the coronal view in SSFP still cine image (f), where it also demonstrates the presence of aortic regurgitation (arrow). (e) Zoomed still cine images in SSFP sequence of the mitral valve (e.1) and a fused asymmetric bicuspid aortic valve (e.3) Showing in a 4-chambers view a small isointense nodule in the ventricular side of the mitral valve, suggestive of Libman-Sacks endocarditis (arrow) and in the LVOT (arrow in e.2) confirmed by echo, and mild thickening of the fused coronary bicuspid cusp (arrow in e.3). Additionally, images (h.1–3) show a thrombus within the portal vein and its main branches; in (h.1), a venous phase of the CE-MRA shows a contrast defect within the portal vein (arrow) consistent with a thrombus. T1-W axial view of the liver (h.2) shows a hypointense structure within the portal system (arrow), and a T2-W STIR view of the liver (h.3) shows hypointense masses within the main portal branches (arrow) consistent with thrombus. CMR, cardiovascular magnetic resonance; SSFP, steady-state free precession; LVEF%, left ventricular ejection fraction; RV EF%, right ventricular ejection fraction; T2-W STIR, T2-weighted short-tau inversion recovery; FPP, first-pass perfusion; T1-W, T1-weighted; ICA, invasive coronary angiography; LGE, late gadolinium enhancement; PSIR, phase-sensitive inversion recovery; CE-MRA, contrast enhancement magnetic resonance angiography; LVOT, left ventricular outflow tract.
characterization, LGE for detecting myocardial fibrosis, and adequate VHD evaluation.

Sacré et al. evaluated 27 consecutive patients with established diagnosis of APS matched with 81 patients without known cardiovascular disease and who developed CMR. LGE was present in 29.6% of APS patients, with a typical ischemic pattern in 11.1%. Remarkably, myocardial scarring had no electrocardiographic nor Echo evidence. Authors concluded that CMR helps search for myocardial ischemia and myocardial fibrosis in APS patients even if they are asymptomatic (95) as CMR can detect scar in as little as 1 cm³ of tissue.

In patients with different comorbidities and the coexistence of more than one AD, CMR can help to differentiate by dissecting the components and timing of each one, orienting major procedures such as surgical valve replacements in high-risk patients with specific strategies to lower their risk as much as possible (100).

Since VHD is the most frequent CV manifestation in APS but also myocardial fibrosis, silent ischemia, potential HF, and the presence of thrombus in different sizes might be present (68), CMR might be the non-invasive cardiovascular image of choice in these populations for correct and prompt evaluation of all of these manifestations in APS patients.

Echo helps detect many of the CV involvement in APS. It has many advantages, such as broad availability and the possibility of performing the study on the patient’s bed and in hemodynamically unstable ones. As a single modality, it is cheaper. However, it cannot detect the earliest involvement related to tissue characterization such as minor myocardial edema, inflammation, or diffuse fibrosis before it can modify global function or even more sensitive techniques such as strain. CMR can identify in a single study the involvement of different components of the CV system, including great vessels, lungs (where are grossly affected by its vasculature), and stress perfusion with high reproducibility allowing the patient to be its control in the future. It would be necessary to gather information from different imaging modalities such as echo, CT, nuclear, etc., impacting more tests, radiation exposure, and costs (101).

See Table 3 for detailed CMR offerings to APS and Table 1 for pros and cons over other imaging modalities.

**Rheumatoid Arthritis**

**General Description**

RA is a chronic autoimmune inflammatory arthritis that affects the joints and other systems, including the heart and CV system, even associated with the early development of atherosclerosis (102, 103) and increased vascular morbidity and mortality (104–109). CVD is the most common cause of death in the general population; these patients have up to 50% mortality and twice the risk of myocardial infarction. This is mainly related to individual genetics and a chronic and prolonged inflammatory activity where specific autoantibodies, cytokines, necrosis tumor factors, and matrix-degrading enzymes contribute to heart and atherosclerotic damage (110).

Therefore, many efforts to identify patients at risk of CVD have been made through different approaches. It has been demonstrated that patients have hidden or incipient damage during the AD diagnosis (110). Patients with RA have a broad spectrum of CV damage during their natural history, including the early presentation of left ventricular (LV) dysfunction (103) without other attributable causes. Early identification of cardiac abnormalities is crucial because it parallels other risk factors of this systemic disease (111–113), and the coexistence of CVD reduces survival (106, 114–116). It is also worrisome that in subclinical patients with RA, regularly evaluated with Echo, the LV global systolic function is reported as normal with diastolic dysfunction, frequently reported adequate to the age of the patient; however, when those same patients are evaluated with CMR (Figure 4a.1–2), it shows regional wall motion abnormalities with reduced circumferential strain at mid-ventricular level with LGE of non-coronary pattern often located in the inferolateral segment at basal and mid-ventricular levels (114–116).

Animal model studies have investigated the correlation between the clinical phenotypes of RA and the inflammatory state to correlate the inflammatory activity with the biomarkers and findings in non-invasive imaging modalities (117), which have been reproduced in humans with the disease (118–121).

---

**Table 3 | CMR offerings to the APS.**

| Pathophysiology | CMR offer | Sequences |
|-----------------|-----------|-----------|
| **What has CMR to offer in antiphospholipid syndrome?** | | |
| VHD: | Assessment of hemodynamic significance. | Cine—SSFP, cine-FGE |
| Libman-Sacks endocarditis | Reproducible follow-up. | Phc, 4D-flow |
| Intracardiac thrombosis | High resolution. Location. Tissue characterization. | Cine—SSFp, T1-W, T2-W |
| | Assessment of hemodynamic significance. | LGE |
| | Reproducible follow-up, free of radiation. | Early LGE, Long T1LGE |
| Pulmonary hypertension | The severity and hemodynamic significance. | Cine—SSFp, Real-time cine |
| | Orientation to the potential etiology. | 4D-flow, MRA |
| RV dysfunction | The gold standard for RV function | Cine—SSFp, Strain |
| LV dysfunction | The gold standard for LV function | Cine—SSFp, Strain, diffusion tensor |
| Myocardial edema | Identification and quantification | T2-W, T2-W-STIR, T2-mapping |
| Myocardial ischemia | Follow up | Stress FPP |
| Myocardial infarction | For microvascular circulation | LGE, LGE, T1 mapping, ECV |

*Can also be related to other processes such as myocardial ischemia, pulmonary hypertension, or dilated cardiomyopathy.*

VHD: valvular heart disease; SSFP, steady-state free precession; FGE, fast gradient echo; Phc, Phase contrast; T1-W, T1-weighted; T2-W, T2-weighted; LGE, late gadolinium enhancement; T1, inversion time; MRA, magnetic resonance angiography; FPP, first-pass perfusion; ECV, extracellular volume.
It is common to find the association with other comorbidities that makes it challenging to identify the specific cause of damage to the CV system, increasing its risk (122). Common comorbidities are systemic arterial hypertension, diabetes mellitus (123, 124), chronic kidney disease (125), and obstructive sleep apnea (126). These comorbidities usually do not have a proper evaluation and treatment (127). Therefore, action is needed to investigate the interaction between the inflammatory state and the presence of these diseases with cardiovascular involvement (115).

**Clinical Manifestations of CV Involvement and Pathogenesis of Cardiac Manifestations**

Cardiac involvement in RA includes VHD in 9% of cases (128). The most commonly affected is the aortic valve, by thickening of its leaflets (*Figure 4d*) or frequently by producing stenosis (129, 130). Ischemic heart disease in 8% of cases (104, 128, 131), myocardial damage that usually remains subclinical (132, 133), and the development of HF of different degrees until reaching its congestive form in 10% of cases (104, 130, 134). Myocardial damage involves diverse causes, which are well described, including subclinical concentric LV hypertrophy, which is considered one of the earliest CV involvement (135–140), microvascular dysfunction, CAD, myocardial ischemia, myocarditis in 6% of cases (130, 141, 142) (*Figure 4b.1–4*), myocardial fibrosis (142, 143) (*Figure 4c.1–5*), dilated cardiomyopathy (141), pericardial effusion in 21% of cases (130), pericardial inflammation (*Figure 4c.1–3,5*), rhythm disturbances in 22% of patients of which 20% have conduction blockades (130), pleural effusion in 9% of cases (130), pleural inflammation (*Figure 4c.4*) and pulmonary fibrosis in 6% of cases (130). Great vessels are also involved; it is described as
abnormal LGE, aortic compliance, and its pulse wave velocity (117, 144) reflecting aortic stiffness (Figure 4f).

The incidence of congestive HF is approximately 2-fold higher than the general population (134).

The pathophysiological mechanisms are related to myocardial inflammation (Figure 4b.2,4), vascular remodeling, alterations in the extracellular matrix (Figure 4b.4), edema (Figure 4b.1,3), and myocardial injury demonstrated by circulating biomarkers, histology, and non-invasive imaging findings (145); premature atherosclerosis and the coexistence with other comorbidities as mentioned before. Interestingly, some areas of myocardial fibrosis match the cardiac conduction system in patients with intracardiac blockades (Figure 4c.4) that are not attributable to CAD or system degeneration.

RA patients are at increased risk for developing PH and right HF. The underlying mechanisms are interstitial lung disease, vasculitis, and chronic thromboembolic disease (146).

There are robust biomarkers for prognosis and therapeutics based on specific CMR findings (147). It is essential to identify early PH in these patients since findings with current non-invasive strategies are available (146). Frequently, the conventional Echo measurements do not provide all relevant information, mainly related to the RV function.

**CMR Role**

It has been proven that laboratory tests and specific inflammation imaging markers can predict the incidence of CV events (145, 148–153). Therefore a comprehensive CMR study is considered a valuable and minimally invasive diagnostic tool to assess cardiac involvement in asymptomatic and symptomatic RA patients (154); since it helps in the timely monitoring of the treatment response and early detection of the various structural and functional cardiac abnormalities (113), including the acceleration of atherosclerosis from the systemic inflammation (148, 155–158).

CMR can identify the indirect signs of PH in the same comprehensive study done to analyze the rest of the cardiac involvement of this disease (Figure 4e.1–3), constituting one of the complete non-invasive diagnostic modalities since it enables the evaluation of function and morphology of PA and RV (147). The findings are the gold standard measurements of RV function (147), systolic shift of the interventricular septum toward the LV, flow measurements, strain analysis with myocardial feature tracking, which can detect RV dysfunction even with normal RV ejection fraction (147), 4D-flow allowing more accurate and multiloculation flow analysis simultaneously (159), LGE in RV which is associated with worse prognosis (147), T1 mapping that detects interstitial fibrosis even without evident LGE (147).

Interestingly, in those patients with cardiac sarcoid, in some cases of RA, it is possible to visualize mediastinal extracardiac tissue (Figure 4g).

See Table 4 for detailed CMR offerings to RA and Table 1 for pros and cons over other imaging modalities.

**Systemic Sclerosis**

**General Description**

SSc is a connective tissue disease classified based on skin involvement into two forms: diffuse cutaneous systemic sclerosis (DcSSc) and a focal, called limited cutaneous systemic sclerosis (LcSSc), previously known as CREST syndrome (160). LcSSc and DcSSc are associated with various systemic manifestations and autoantibody positivity. ANA may be present in more than 90% of cases of systemic sclerosis, and at least one of the more specific autoantibodies (anti-centromere, anti-SCL70, and anti-RNA polymerase III) is present in up to 70% of cases (161). The organs most frequently affected by scleroderma are the skin, gastrointestinal tract, lungs, kidneys, skeletal muscle, and the heart (161).

**Clinical Manifestations of CV Involvement and Pathogenesis of Cardiac Manifestations**

Cardiac involvement is reported high in histopathological reports as in CMR studies, reaching 75–80% of patients with this disease (162). The cardiovascular clinical presentation most commonly includes the lungs with nonspecific interstitial pneumonitis, interstitial pneumonia, and PH (163). In the heart (Figure 1), both forms of SSC (164) includes pericardial inflammation (Figure 5c.1–5) with clinical presentation of pericarditis in 10–20% of cases (165), pericardial effusions with fibrosis (Figure 5c.1–5) and thickening that reaches constrictive pericarditis, and myocardial involvement, with edema (Figure 5b.1) presenting as myocarditis that could be even fulminant (164, 166), and fibrosis (Figure 5c.1–5), which characteristically affects both ventricles (166, 167) that progresses to conduction disturbances, such as conduction blockades, atrioventricular or intraventricular in 28–52.8% of cases on resting ECG or 38–56% of cases on 24-h Holter monitoring (168) or ventricular arrhythmias; and progressive cardiac dilation

| Table 4 | CMR offerings to the RA. |
| --- | --- |
| **Cardiac manifestation** | **CMR utility** | **Sequences** |
| What has CMR to offer in rheumatoid arthritis? | | |
| LV dysfunction | The gold standard for LV function. | Cine—SSFP, strain, diffusion tensor |
| Myocarditis | Identification and quantification. | T2-W-STIR, T1, T2-mapping, ECV, LGE-PSIR |
| Myocardial fibrosis | Identification, location, and quantification. | T1, T2-mapping, ECV, LGE-PSIR |
| Heart failure | The gold standard for RV and LV function. | Strain, diffusion tensor |
| Vascular involvement | Great vessels – Aortic involvement | Cine—SSFP, cine-FGE, 4D-flow, MRA |

SSFP, steady-state free precession; T2-W, T2-weighted; STIR, short tau inversion recovery; LGE, late gadolinium enhancement; PSIR, Phase-sensitive inversion recovery; MRA, magnetic resonance angiography; ECV, extracellular volume.
and systolic-diastolic dysfunction ending up in HF (164). Diastolic dysfunction is the most common finding, reported in 30 (165) to 44% of cases (169), may be related to the broader use of Echo as the initial, and sometimes, a unique diagnostic tool for the evaluation of the involvement of the heart in this disease. Some reports also describe VHD (167).

The pathophysiological mechanisms affect mainly the lungs with vascular damage, autoimmunity, loss of pulmonary microvasculature (163), and tissue fibrosis. It is non-inflammatory proliferative/obliterative vasculopathy followed by interstitial/vascular fibrosis (170). Perivascular inflammatory infiltrates of CD4+ T lymphocytes may be seen early in the disease but are absent at long-standing stages. This vasculopathy is characterized by mild intimal proliferation and basement membrane thickening, loss of vascular endothelial cadherin, platelet aggregation, and microthrombus formation. The presence of vasculitis or immunocomplex deposition is infrequent. Over time in long-standing cases, there is extensive perivascular fibrosis, progressive luminal occlusion, and tissue fibrosis (171), making the vascular reactivity fixed and irreversible. Similar pathophysiology as lung vessels affects the microvasculature in the heart producing myocardial necrosis and chronic small vessel vasculopathy similar to the one in Raynaud’s phenomenon (167).

It has been reported that the positivity of Anti-topoisomerase I autoantibodies is associated with cardiac involvement (172). The clinical markers of risk for the development of systolic dysfunction are the male gender, older ages, the coexistence of digital ulcers, and skeletal muscle involvement (172).

**CMR Role**

CMR evaluation of these patients allows for assessing the right-sided heart. It shows that, even in the absence of PH, there are hemodynamic abnormalities manifested as right atria and ventricle enlargement, which increases progressively along with the vascular resistance and the pulmonary artery systolic pressure (PASP) with the establishment of PH and finally with RV dysfunction in 5–10% of cases (165, 169). CMR cannot measure the PASP directly; however, some indirect findings orient to the presence of PH and correlate well with the invasive measurement of PASP; one important finding is the systolic shift of the interventricular septum toward the LV, when this finding is observed in CMR the PASP is usually higher than 67 mmHg; therefore, the patient is with at least moderate PH (173).

Interestingly, even with the detection of myocardial edema (Figure 5b.1), focal and diffuse fibrosis (Figure 5c.1–5) by CMR, and the presence of a certain degree of LV dysfunction present in 5% of cases (165), the clinical presentation of HF is uncommon in these patients, with only 5% manifesting the same (174). LGE in SSc has a typical pattern of non-ischemic cardiomyopathy (Figure 5c.1–5), with non-coronary distribution as in other ADs, with a linear mid-wall distribution, even in subclinical and early-stage cases; without significant impairment of cardiac function at that time (175) (Figure 5a.1,2). As in ischemic patients with

---

**FIGURE 5 |** CMR findings in SSc. A panel figure demonstrates varying findings by a comprehensive CMR study at 1.5 Tesla scanner of SS. (a) SSFP sequence still cine images in short-axis view at the mid-ventricular level in end-diastole (a.1) and end-systole (a.2) shows normal global and regional functions of both ventricles, LVEF 57% and RVEF 56%. (b.1) T2-W STIR sequence in short-axis view at the mid-ventricular level of normal myocardium and myocardial/skeletal muscle ratio. (b.2) T1 mapping with a native T1 of 998 ms (mildly increase) and a calculated ECV of 32% (mildly increase). (c.1–3) LGE PSIR sequence. (c.1–3) Short-axis views at basal (c.1), mid (c.2), and apical (c.3) levels, and long-axis views in 4-chambers (c.4) and 3-chambers (c.5). The arrowheads in these images show areas of focal fibrosis as mid-wall LGE of the anteroseptal segment in (c.1) and the subepicardium of the inferior segment in (c.1–3) in the basal and mid anterolateral segments in (c.4) and subendocardial in the LV apex in (c.5). In addition, the same set of images shows LGE of the pericardium without effusion (arrow), suggestive of pericardial inflammation. CMR, cardiovascular magnetic resonance; SS, systemic sclerosis; SSFP, steady-state free precession; LV EF%, left ventricular ejection fraction; RVEF%, right ventricular ejection fraction; T2-W STIR, T2-weighted short-tau inversion recovery; ECV, extracellular volume; LGE, late gadolinium enhancement; PSIR, phase-sensitive inversion recovery.
a higher LGE burden, ventricular arrhythmias have a stronger association, supporting the hypothesis of a fibrotic substrate for this kind of rhythm disturbance. According to the SAnCiUS score, the significant T2-STIR myocardium/skeletal muscle ratio (>2.3) and the presence of more than 5% of LGE of the LV mass can predict the development of potentially life-threatening ventricular arrhythmic events (176).

T1 mapping and ECV values are significantly higher in patients with SSc than in healthy controls (Figure 5b). In addition, a higher burden of diffuse myocardial fibrosis measured by mapping techniques, higher native T1 value (Figure 5b.2), and increased ECV have been associated with more severe interstitial lung disease (177). The potential role of this technique in avoiding the additional risks and costs of using the current gold standard method, the endomyocardial biopsy (178), remains unclear. Still, well-designed studies are helping to answer that question correctly.

The UK Systemic Sclerosis Study Group proposed a comprehensive algorithm that classifies patients as asymptomatic, at-risk, and symptomatic for cardiac complications, including the standard assessment including patient history, blood pressure, lipid profile, and HbA1c, ECG, Echo, a core set of parameters to be measured at each Echo and laboratory parameters; the follow-up intervals are determined by the risk categorization. In this context, CMR is recommended in a more individualized analysis, depending on the clinical manifestation of each patient independent of their risk categorization in the algorithm (179). See Table 5 for detailed CMR offerings to SSc and Table 1 for pros and cons over other imaging modalities.

### Adult-Onset Still’s Disease

#### General Description

AOSD is a non-hereditary, non-organ specific, polygenic autoinflammatory disease that affects young adults in a bimodal distribution with an average age of 15–25 and 36–46 years old and an incidence of 0.16–0.4/100,000 individuals (180). Its pathogenic mechanism involves a genetic background with triggering factors that generate a dysregulated immune activation with overproduction of inflammatory cytokines, principally IL-1, IL-6, and IL-18, and a deficiency of anti-inflammatory mechanisms (181).

Based on the Yamaguchi diagnostic criteria, the main clinical manifestations are the presence of febrile peaks, non-pruritic erythema, arthritis, polyserositis, odynophagia, lymphadenopathy, and hepatosplenomegaly. Associated with elevated serum biomarkers such as leukocytes, globular sedimentation rate, and ferritin (165).

### Clinical Manifestations of CV Involvement and Pathogenesis of Cardiac Manifestations

It affects the CV system within the spectrum of systemic alterations (Figure 5). This disease mainly affects serosal layers; therefore, it presents with pericarditis in 37% of cases with CV involvement. Pericarditis can evolve until tamponade, but it is rare. Other described forms of cardiac involvement are endocarditis and myocarditis, which are present in 7% of cases (180, 182, 183).

Common clinical CV manifestations are chest pain, dyspnea, tachycardia, atrial gallop, pericardial rub, and pulmonary congestion; physical examination data, all manifestations according to LV systolic dysfunction and the progression to HF even to cardiogenic shock. The development of cardiogenic shock is considered the second cause of mortality in these patients, accounting for 4.2% in the acute event and up to 21% in 1 year (180, 184). Interestingly, this disease shows non-specific ST segment and T wave alterations often in the acute event (79% of cases) (185), probably related to concomitant non-obstructive involvement of coronary arteries not well described till today (180, 184, 186). Usually, myocarditis occurs early in the evolution of SD, and it has been reported in the adult-onset of SD in 54% of the cases (185).

It is not surprising that the presence of myocarditis, which is often symptomatic in 96% of cases, with electrocardiogram abnormalities mentioned above and LV dysfunction with reduced LVEF ≤50% in 67% of cases (185); can manifest with arrhythmias and ventricular dysfunction as it has been described, based on the cytokine storm that is part of this disease (180, 184, 186). CMR has good diagnostic accuracy in this disease (182, 187, 188) and can demonstrate the presence of myocarditis found with the endomyocardial biopsy (185). It is crucial to identify the presence and severity of cardiac involvement, mainly in myocarditis cases. Still, the LV dysfunction is not evident since the conventional therapy with steroids alone is effective only in 50% of cases with myocarditis. Few of them can evolve

| Cardiac manifestation | CMR utility | Sequences |
|-----------------------|-------------|-----------|
| What has CMR to offer in systemic sclerosis? | Identification and quantification. | T2-W-STIR |
| | Follow up free of radiation. | T1, T2-mapping, ECV |
| | | LGE-PSIR |
| Myocarditis | Identification. | Cine—SSFP |
| | Measurement of pericardial thickness. | Free-breathing |
| | Detection of inflammation. | real-time cine |
| | Detection of constriction. | T1-W, T2-W STIR |
| | Follow up free of radiation. | LGE-PSIR |
| Pericarditis | Identification. | Cine—SSFP |
| | Orientation to the potential etiology. | 4D-flow |
| | | MRA |
| Pulmonary hypertension | The severity and hemodynamic significance. | Cine—SSFP |
| | Chair | Real-time |
| RV dysfunction | The gold standard for RV function | Cine—SSFP |
| | | Strain |
| LV dysfunction | Diastolic | T1, T2 mapping, ECV |
| | | LGE-PSIR |
| | Systolic: The gold standard for LV function. | Cine—SSFP |
| | | Strain, diffusion tensor |

SSFP: steady-state free precession; T2-W, T2-weighted; STIR: short tau inversion recovery; LGE, late gadolinium enhancement; PSIR, Phase-sensitive inversion recovery; MRA, magnetic resonance angiography; ECV, extracellular volume; PHC, phase contrast.
As mentioned above, in the early stages of the disease, the myocardial and serosal involvement could course asymptomatic, leading to a misdiagnosed entity. Despite high-level serum inflammatory biomarkers or unspecific ECG changes, it is only suspected when there is clinical evidence of HF. Therefore, the evaluation of CMR with T1-weighted, T2-weighted, and post-gadolinium enhancement allows in a non-invasive manner with good sensitivity and specificity the early detection of cardiac involvement, tissue characterization, and left ventricle function, helping in the prompt initiation of steroids, biotherapies or neurohumoral blockage in cases of systolic dysfunction since it increases morbidity and could be potentially fatal.

See Table 6 for detailed CMR offerings to SD and Table 1 for pros and cons over other imaging modalities.

### Table 6 | CMR offerings to the AOSD.

| Cardiac manifestation | CMR utility | Sequences |
|----------------------|-------------|-----------|
| LV dysfunction       | The gold standard for LV function | Cine—SSFP, Strain, diffusion tensor |
| Myocarditis          | Identification and quantification; Follow up free of radiation | T2-W-STIR, T1, T2-mapping, ECV, LGE-PSIR |
| Pericarditis         | Identification, Measurement of pericardial thickness; Detection of inflammation; Detection of constriction; Follow up free of radiation | Cine—SSFP, Free-breathing, real-time cine, T1-W, T2-W STIR, LGE-PSIR |
| Tamponade            | Identification, Assessment of severity and hemodynamic significance, detection of inflammation | Cine—SSFP or SSr, Free-breathing, real-time cine, LGE-PSIR |

SSFP, steady-state free precession; T2-W, T2-weighted; STIR, short tau inversion recovery; LGE, late gadolinium enhancement; PSIR, Phase-sensitive inversion recovery; ECV, extracellular volume; SSr, single-shot.

### Polymyositis and Dermatomyositis

#### General Description

An idiopathic inflammatory myopathy presents proximal, and symmetric muscle weakness due to inflammatory infiltrates in the skeletal muscle. In some cases, it has extraskelatal and muscular involvement in the skin, the lung, the joints, the heart, and distal arteries with Raynaud's phenomenon (189).

It presents after the second decade of life and is more common between 45 and 60 years; females are mostly affected with a ratio of 2:1 (190).

Genetically is associated with the major histocompatibility complex (MHC) at chromosome 6, at the HLA-DRB1*03:01 and HLA-B*08:01 alleles of the ancestral haplotype 8.1 (8.1AH) (190).

The usual clinical presentation is symmetric proximal muscle weakness (in >90% of cases in PM and >50% in DM) with skin manifestations in DM. The onset of symptoms can be in days or more insidious, weeks or even months, with fever, malaise, weight loss, asthenia, and adynamic. Muscle atrophy is a late complication in advanced disease. In DM, the rash often precedes or accompanies muscle weakness. Cutaneous manifestations can be pathognomonic as (1) Gottron’s papules, which involve extensor regions such as the knuckles, elbows, or knees, (2) heliotrope rash involving the periorbital region with or without edema, (3) erythematous rash on the chest, back in regions exposed to the sun, (4) facial erythema or a malar rash that does not spare the nasolabial fold, (5) periangual hyperkeratosis and telangiectasias, which represent rings of capillary dilation in the nail matrix, (6) dermal ulcers related to vasculopathy, (7) calcinosis of the subcutaneous tissue in the muscular fasciae, (8) lipodystrophy and hyperkeratosis with cracks in the palms (190, 191).

### Clinical Manifestations of CV Involvement and Pathogenesis of Cardiac Manifestations

Cardiac involvement in Polymyositis (PM) and dermatomyositis (DM) derives from exposure to an inflammatory process for a specific time, which causes structural and functional alterations of the heart. The affected cardiac structures are the valves, the conduction system, the myocardium, the endocardium, the pericardium, and the pulmonary and coronary arteries (192) (Figure 1).

Heart valves are affected due to the ongoing inflammatory process, causing leaflet thickening and dysfunction. Although rare, the aortic (46.7%) and the mitral (20%) valves are most frequently involved, often producing stenosis. Interestingly, mitral stenosis could be the primary manifestation in up to 6.7% of cases depicted by Echo studies (193).

The histologic substrate is lymphocytic infiltration of the conduction system and the fibrosis of the sinoatrial node (194).

Aside from the VHD previously described, it is common to identify conduction system disturbances at different levels, manifested with a diverse degree of severity and location of His bundle and its branches in 33–72% of cases (194) or arrhythmias identified in 52–88% of cases, where the most common are supraventricular tachycardia, premature ventricular complexes, ventricular tachycardias, and atrial fibrillation. Frequently,
supraventricular tachycardias, including atrial fibrillation, are present in 12–50% of patients developing myocarditis (195).

In PM, it is frequent to encounter the presence of LV hypertrophy easily assessed by Echo (194). Interestingly, many patients with this disease and cardiac involvement remain subclinical. Therefore, high suspicion is necessary, and the role of CMR is crucial for the timely identification of cases likely to develop these complications so they can receive appropriate, timely, and specific treatment responsive to appropriate immunosuppressive therapy (196, 197).

In PM and DM, it is common to identify HF in a variable range from 32 to 77%, which could be diastolic or even severe systolic dysfunction (197). Patients have LV dysfunction.

Myocarditis has been described in up to 8% of cases (196). Myocardial ischemia has been described in 26% of patients with PM/DM; the main symptoms are angina (4%) and exertion dyspnea (18%), although the latter could be associated with ventricular dysfunction (198). The underlying mechanisms are related to the inflammatory state that produces acceleration in coronary atherosclerosis, rapid progression of CAD, and making early stages of atheromatous plaques prone to instability favoring the presence of an acute coronary syndrome due to their rupture (198). LV dysfunction is associated with an increase in ventricular filling pressures contributing to a reduction in coronary perfusion pressure, predisposing patients to developing myocardial ischemia independent of the presence of CAD (198).

As in other ADs, the association between PM/DM and aseptic endocarditis has been described. However, in this case, it is an infrequent entity with possibly catastrophic consequences if not diagnosed in time (199).

Pericarditis is reported in 4–25% of adults with PM/DM, and most of them remain asymptomatic and hemodynamically insignificant (200). The exception is in those patients with the PM that are positive for anti-Jo, anti-Mi, and anti-SRP antibodies (201). The anti-Jo-1 is the primary antibody that defines the antisynthetase syndrome (202, 203), and the other antibodies support the diagnosis. The most specific antibody for DM is the anti-Mi-2 (204), where the anti-SRP is present in the immune-mediated necrotizing myopathy variant (205). In the antisynthetase syndrome, the incidence of pericarditis is higher, 50%, and it tends to have more significant hemodynamic repercussions, even reaching cardiac tamponade (195).

PH is a life-threatening entity that culminates in severe right ventricular dysfunction and HF. In PM patients with the antisynthetase syndrome, PH is present in 8% of cases, which are very ill (195).

**CMR Role**

CMR shows LGE in the non-coronary territory consistent with non-ischemic cardiomyopathy, reported in 62.3% of cases consistent with myocarditis (197). CMR findings are compatible with myocardial inflammation, mainly located in the inferior and lateral segments of the LV (197).

The presence of LGE in PM/DM has similar behavior to Duchenne muscular dystrophy (206, 207). It needs careful interpretation since it appears that the presence of LGE could have a protective effect on LV systolic global function.

**TABLE 7** | CMR offerings to the PM/DM.

| Cardiac manifestation | CMR utility | Sequences |
|-----------------------|-------------|-----------|
| What has CMR to offer in polymyositis/dermatomyositis? | | |
| Valvular disease | Assessment of hemodynamic significance. Reproducible follow-up. | Cine—SSFP, cine-FGE, PhC, 4D-flow |
| Pulmonary hypertension | The severity and hemodynamic significance. Orientation to the potential etiology. | Cine—SSFP, Real-time cine, 4D-flow, MRA |
| Myocardial edema | Identification and quantification. Follow up | T2-W, T2-W-STIR, T2-mapping |
| Myocarditis | Identification and quantification. Follow up free of radiation. | T2-W-STIR, T1, T2-mapping, ECV LGE-PSIR |
| Myocardial inflammation | Identification and quantification. Follow up free of radiation. | T1-W pre, and post-Gd, T1 mapping, ECV LGE-PSIR |
| RV dysfunction | The gold standard for RV function | Cine—SSFP, Strain |
| LV dysfunction | The gold standard for LV function | Cine—SSFP, Strain, diffusion tensor |

SSFP, steady-state free precession; FGE, fast gradient echo; T2-W, T2-weighted; STIR, short tau inversion recovery; LGE, late gadolinium enhancement; PSIR, Phase-sensitive inversion recovery; ECV, extracellular volume; MRA, magnetic resonance angiography; Gd, gadolinium.

In a large cohort of PM/DM, the authors found reduced LV function in 17% of the patients, and all showed LGE; however, in the remaining patients, with normal LV systolic global function, up to 54.5% of them had LGE. This suggests that fibrosis may be an earlier change in the myocardium and precedes the establishment of LV systolic global dysfunction (197). See Table 7 for detailed CMR offerings to PM/DM and Table 1 for pros and cons over other imaging modalities.

**Eosinophilic Granulomatosis With Polyangiitis (Formerly Churg-Strauss Syndrome)**

**General Description**

Churg-Strauss syndrome, renamed eosinophilic granulomatosis with polyangiitis (EGPA), is a systemic vasculitis characterized by disseminated necrotizing vasculitis and extravascular granulomas (34). EGPA is a rare vasculitis, often insidious and underestimated, classified as small and medium-sized vessel vasculitis associated with antineutrophil cytoplasmatic antibodies (ANCA) and the hypereosinophilic syndrome (208). It affects multiple organ systems, especially the lungs. Its pathophysiology includes the presence of hypereosinophilia, inflammation of blood vessels producing vasculitis, and nodular inflammatory lesions as granulomas.
Clinical Manifestations of CV Involvement and Pathogenesis of Cardiac Manifestations

Heart involvement has been described in 15–60% of cases, mainly in those antineutrophil cytoplasmic antibodies (ANCA) negative (208) and includes myocarditis, pericarditis, conduction disturbances manifested by different types of arrhythmias (most commonly heart block), valvular heart disease, intracavitary thrombosis, coronary arteritis, LV dysfunction, and HF (208–210) (Figure 1). The timing for CV involvement varies; it is usually an early manifestation of the disease but could be a later presentation (208). An important problem is that almost 40% with cardiac involvement remain asymptomatic and have no significant ECG abnormalities (208, 210). Patients with cardiac involvement have a poor prognosis and are responsible for 50% of the deaths of this disease (208–212). Therefore, all asthmatic patients with dyspnea, vasculitis, and hypereosinophilia suspected of EGPA cardiac involvement should be considered (207) since early identification and diagnosis of the cardiac involvement and proper treatment may prevent the progression of the cardiac disease (203).

The early diagnosis of cardiac involvement is crucial because the prognosis is poor once HF is established (213), even though some are still reversible (210, 212).

Myocarditis in this syndrome is the most severe manifestation (210, 212). It could be the first manifestation and eventually cause a fatal outcome (212, 214), presenting early or late in the disease in 59% of cases (210, 212, 215). It is typically characterized by myocardial infiltration predominantly of eosinophils, mainly caused by eosinophilic granule proteins, specifically the eosinophil cationic protein (216). It has features that should raise suspicions, such as reduced global systolic function with diffuse LV hypokinesia, increased wall thickness, total LV mass with marked myocardial edema, and diffuse subendocardial eosinophilic infiltrate (209, 216). Myocardial injury directly affects eosinophil-mediated necrosis and induction of apoptosis rather than myocardial vasculitis (211).

Its response to treatment is variable (207, 209, 210) and sometimes results in cardiogenic shock (217). A systematic review of the literature showed that myocarditis is more prevalent at younger ages. The worst prognosis is at younger ages; males are affected at younger ages than females. Usually, the patients have a previous history of severe asthma; when the eosinophils are >20% of the white blood cells count, they start to infiltrate into the myocardium and are associated with negative ANCA status (206, 213, 216).

Intracavitary thrombosis is attributed to the subendocardial eosinophilic infiltration in localized ventricular segments with impaired function (212) and its procoagulant effect in the hypereosinophilic state. Thrombosis could be localized or massive, involving both ventricles (209, 211).

The involvement of the pericardium could be as inflammation with pericarditis or, more often, as the pericardial effusion of varying degrees of severity reported in 41% of the cases with cardiac involvement (210, 212). Pericardial involvement could be isolated, have a more benign presentation, might cause congestive symptoms, rarely tamponade (215, 218), and even atraumatic intrapericardial thrombosis (219).

The conduction disturbances are frequent with cardiac involvement; however, life-threatening arrhythmias are rare and often asymptomatic (220). Complete heart block has rarely been described (221, 222). The pathophysiological mechanism behind ventricular tachycardias in EGPA is abnormal automaticity, possibly due to myocardial ischemia secondary to necrotizing vasculitis of small and medium-size arteries (220) and heart block due to infiltration of the myocardium and the His-Purkinje system (221). These arrhythmias are one of the leading causes of sudden cardiac death in these patients (220).

VHD is presented in as high as 73% of cases (212); however, it mostly only affects the aortic and mitral valves to a mild degree, but some severe cases have been described, usually mitral regurgitation (221, 223). The pathophysiology of the VHD shows necrotizing granulomatous inflammation with eosinophils infiltrating the valve leaflets, with marked thickening, in part due to fibrosis and mainly to an intense inflammatory reaction for the aortic valve (221) and the mitral valve, also related to endomyocardial fibrosis involving the papillary muscles (221, 224).

LV dysfunction has been described in as high as 50% of the cases (210, 212). Patients that develop myocarditis have less function recovery and a worse prognosis (210, 212). Studies with Echo and CMR showed that in addition to the systolic dysfunction, they have impairment of ventricular relaxation (223). The pathophysiology of that dysfunction has been suggested as myocardial edema, fibrosis (218), and eosinophilic myocardial infiltration (225); but can coexist with epicardial coronary vasculitis and resultant MI (218, 226).

RV dysfunction accompanying LV dysfunction is prominent in EGPA, as demonstrated by Echo (223) and CMR. Still, the solo presentation is highly unusual, with the typical 3-layer appearance and thrombus formation with the subendocardial LGE (227).

HF is uncommon (228–230) in around 4% of cases with EGPA (212). Still, some patients develop dilated cardiomyopathy, which may be reversible with early diagnosis and proper treatment, or could die due to HF. Interestingly, these patients are ANCA negative and have high eosinophil counts (212). These patients have intracardiac thrombus, which can embolize the brain and be the origin of stroke, an independent cause of associated brain vasculitis (230).

Coronary artery involvement in EGPA is often with arteritis (209) and rarely vasospasm (231–234). The pathophysiological mechanism is myocardial ischemia due to the sudden severe reversible vasoconstriction of a normal or diseased epicardial coronary artery (231, 233). Vasospasm has been suggested due to eosinophilic infiltration of the coronary artery wall that directly stimulates vascular smooth muscle contraction and adventitial nerve fibers (236) by their proteins and vasoactive cytokines (231, 237). Other coronary artery abnormalities are due to direct damage to the vascular tissues that predisposes it to dilatation, aneurysmal formation (233) with a higher propensity to dissection (238), and thrombus formation (239), which finally produces fibrosis of the intima and media layers of the vessel wall (236). These patients have a higher risk of recurrent coronary events despite the
medical treatment for conventional atherosclerotic coronary vasospasm (237).

Pulmonic venous thrombosis has been reported with a prevalence of 8.1% (240) that could present at first diagnosis or remission (241). It presents in ANCA negative patients (242). The pathophysiological mechanisms remain unclear and speculative (243), but it seems to be related to the prothrombotic properties of the eosinophil granule proteins, such as the cationic proteins that can bind the Hageman Factor (XII) and activate the intrinsic pathway of coagulation and interfere with the anticoagulant activity of endogenous heparan sulfate (in vitro) (244), along with the potential role of other eosinophil products such as the hypothiocyanous acid by the induction of tissue factor activity (245).

CMR Role
CMR allows functional analysis along with the pathophysiological assessment of the different components of the CV involvement described in detail in the above section by the detecting myocardial edema in the myocarditis, identifying and quantifying myocardial fibrosis, and the scars related to arteritis or coronary arteries occlusions (246).

LGE in EGPA can be at mid-wall, epicardial, transmural, and often subendocardial locations (247, 248). These former two mainly with coronary artery distribution secondary to the arteritis, spasm, or even thrombotic occlusions (246). Using edema sequences, it is possible to discriminate the “age” of the LGE in that an acute lesion will have matching areas of myocardial edema and LGE, while chronic lesions will only show LGE without the corresponding matching edema area. Currently, the edema sequence using a T2-W image can be improved in detecting edema by using quantitative T2 mapping (249). Related to the diffuse fibrosis presence in this disease, it is helpful to include T1 mapping sequences and the ECV that has been demonstrated to have a good correlation with interstitial myocardial fibrosis in histology and clinically with the decrease of LVEF% (250) even before other methods such as Echo, and functional CMR would detect. See Table 8 for detailed CMR offerings to EGPA and Table 1 for pros and cons over other imaging modalities.

Dress Syndrome
General Description
DS is defined as Drug Reaction with Eosinophilia and Systemic Symptoms (251). DS is a severe, idiosyncratic reaction to a drug characterized by a prolonged latency period. There are a variety of non-cardiac manifestations such as fever, rash, lymphadenopathy, eosinophilia, and other systemic presentations. Cardiac involvement is reported rarely; however, its actual incidence remains unknown because it is frequently misdiagnosed (252) (Figure 1). DS has been associated with some autoimmune substrates, mainly with inflammatory polyarthritis, seronegative spondyloarthritides (253), and ankylosing spondylitis; but also with persons prone to ADs like type 1 diabetes mellitus, Hashimoto’s thyroiditis (254), autoimmune hemolytic anemia (255), autoimmune enteroenteropathy, alopecia areata, SLE, scleroderma lesions, and rheumatoid arthritis in the future (256).

Clinical Manifestations of CV Involvement and Pathogenesis of Cardiac Manifestations
Cardiac involvement varies from 4 to 21% (257) and includes myocarditis and pericarditis (258). Myocarditis can be fatal and under-diagnosed, and it may occur long after the onset of symptoms of the DS (Figure 6b, c.1–3). Its pathophysiological abnormality is myocardial edema (Figure 6b) and inflammation through activated T cell reactions resulting in cytotoxicity and eosinophil activation and recruitment of leukocytes with eosinophils (90%) and/or mononuclear cells (40%) (257, 259). DS produces hypersensitivity myocarditis and acute eosinophilic myocarditis, leading to acute necrotizing eosinophilic myocarditis, cardiac thrombosis, and fibrotic stage (Figure 6c.1–3), corresponding to transient, persistent, or even fatal LV dysfunction (257). Pericarditis (260, 261) could present isolated in rare cases or more frequently associated with myocarditis (Figure 6a.1–3,c.1); these findings are markers of severity of the syndrome.

CMR Role
CMR has only being proposed as part of the diagnostic algorithm as in the EGPA (262) since this syndrome is rare, and maybe underdiagnosed, published information is scarce. A case report from 2018 shows the presence of myocardial edema in an edema CMR sequence, with abnormal T2 mapping consisting with edema and patchy LGE suggesting the presence of myocardial edema, inflammation and fibrosis confirmed by histology obtained with endocardial biopsy (263). Echo can identify the LV dysfunction but not all this tissue abnormalities key to guide treatment and to stabilize prognosis. See Table 9 for detailed CMR offerings to DS and Table 1 for pros and cons over other imaging modalities.

DISCUSSION
Cardiovascular involvement is increasingly recognized and documented as an essential prognosticator for managing autoimmune and inflammatory rheumatic conditions; being recognized that cardiac involvement, a well-documented poor prognostic factor, is a leading cause of mortality. However, given that the condition remains clinically silent during the early stages of the disease process and often remains undetected by routine ECG, Echo, CT, and nuclear studies, increased awareness and a better understanding of the underlying multi-system pathophysiology mechanisms are imperative, with the incorporation of a robust diagnostic non-invasive modality to ensure screening, early detection, diagnosis, prognostication, guide management and follow-up of early cardiovascular involvement in patients with ADs.

In a recent publication from Sacilotto et al. (264), they found in a small cohort that the EULAR criteria are effective at identifying patients with high CV risk and that the Doppler ultrasound in carotids and femoral arteries are tools that can be used in clinical practice to detect CV disease even in their asymptomatic stage. In addition, Aceituno-Melgar et al. (265) found Echo variables that were statistically significant in RA patients and served as early diagnosis of subclinical CV
TABLE 8 | CMR offerings to the EGPA.

| Pathophysiology                  | CMR offer                                      | Sequences                  |
|----------------------------------|------------------------------------------------|----------------------------|
| **What has CMR to offer in eosinophilic granulomatosis with polyangiitis?** |                                                |                            |
| Myocarditis                      | Identification and quantification.              | T2-W-STIR                  |
|                                  | Follow up free of radiation.                   | T1, T2-mapping, ECV        |
|                                  |                                                | LGE-PSIR                   |
| Pericarditis                     | Identification.                                | Cine—SSFP                  |
|                                  | Measurement of pericardial thickness.          | Free-breathing real-time cine |
|                                  | Detection of inflammation.                     | T1-W, T2-W STIR            |
|                                  | Detection of constriction.                     | LGE-PSIR                   |
|                                  | Follow up free of radiation.                   |                            |
| Arrhythmias                      | Substrate identification, location, and quantification. | T1, T2-mapping, ECV        |
|                                  | Prognostic information.                        | LGE-PSIR                   |
|                                  | Follow up free of radiation.                   |                            |
| Valvular heart disease           | Assessment of hemodynamic significance.        | Cine—SSFP, cine-FGE        |
|                                  | Reproducible follow-up.                        | PhC, 4D-flow               |
| Intracoronary thrombosis         | Coronary arteries—atherosclerosis, thrombosis, and vasospasm. | Cine SSFP, Stress FPP      |
|                                  | Microvascular dysfunction                      | LGE-PSIR, MR coronary angiography |
| Coronary arteritis               | Inflammation and thrombosis.                   | Cine SSFP, Stress FPP      |
|                                  | Microvascular dysfunction                      | LGE-PSIR, MR coronary angiography |
|                                  |                                                  | T1-W, T2-W, T2-STIR        |
| LV dysfunction                   | The gold standard for LV function.             | Cine—SSFP                  |
|                                  |                                                  | Strain, diffusion tensor   |
| RV dysfunction                   | The gold standard for RV function.             | Cine—SSFP                  |
|                                  |                                                  | Strain                     |
| Heart failure                    | Systolic: The gold standard for RV and LV function. | Cine—SSFP                  |
|                                  | Fibrosis pattern, location, severity, and quantification. | Strain, diffusion tensor   |
|                                  | Follow up free of radiation.                   | T1, T2 mapping, ECV        |
|                                  | Prognostic information.                        | LGE-PSIR                   |
|                                  | Diastolic                                      | PhC                        |
|                                  |                                                  | T1, T2 mapping, ECV        |
|                                  |                                                  | LGE-PSIR                   |
| Coronary vasospasm               | Vasospasm and myocardial ischemia.             | Cine SSFP, Stress FPP      |
|                                  |                                                  | LGE-PSIR, MR coronary angiography |
|                                  |                                                  | Stress FPP                 |
|                                  |                                                  | LGE-PSIR                   |
| Peripheral venous thrombosis     | Thrombus identification in different organs and vascular territories in the same study.* | T1-W, T2-W, PD, T2-STIR, SSFP, FGE, TOF, PhC, 4D-flow |

*Except for extremities and the brain since those require a dedicated venous MR study of each location.

SSFP, steady-state free precession; T1-W, T1-weighted; T2-W, T2-weighted; ECV, extracellular volume; T2W-STIR, T2 weighted short-tau inversion recovery; FPP, first-pass perfusion; FGE, fast gradient echo; LGE, late gadolinium enhancement; PSIR, phase-sensitive inversion recovery; MR, magnetic resonance; PD, proton density; TOF, time of flight.

Involvement, supporting that even those patients in low risk or even asymptomatic according to EULAR criteria would benefit from a deeper investigation of such involvement.

PH is a common feature of almost all AD, at least in advanced stages; however, the early signs of the pulmonic vasculature involvement are often missed until the late stages, resulting in higher morbidity and mortality rates. In PH, the RV is a critical determinant of the clinical course and response to treatment of these kinds of patients. Early detection of RV dysfunction may offer a better response to therapeutic measurements. CMR allows analysis of function, morphology, and the interactive hemodynamics between PA and RV. Most cine-CMR-derived parameters (volumes and function) and flow-CMR measurements have been suggested as powerful markers for response to treatment and prognosis (147). Recent technological advances have included clinical protocols for PH evaluation that include right ventricular mechanics such as Strain analysis with myocardial feature tracking that allows early detection of subclinical early RV dysfunction. 4D-flow techniques enhance the assessment of this PA–RV binomial allowing the patient risk stratification (266) and important prognostic information gathered for over a decade in other causes of PH (267). Contrast techniques help identify the anatomy in a conventional magnetic resonance angiography, and the same study uses the information.
FIGURE 6 | CMR findings in DS. A panel figure demonstrates varying findings from a comprehensive CMR study at a 1.5 Tesla scanner of DS. (a) SSFP sequence still cine images in short-axis view at the mid-ventricular level in end-diastole (a.1) and end-systole (a.2) show normal global and regional functions of the left ventricle, LVEF 63% and mildly reduce systolic global RV function and mild global hypokinesia RVEF 45%. (a.3) In a coronal view showing the mild pericardial effusion surrounding the heart (asterisks). (b) T2-W STIR sequence in short-axis view at a mid-ventricular level showing increased signal intensity in the septal segments (arrow) with a myocardial/skeletal muscle ratio of 2.3, suggesting mild myocardial edema. (c.1–5) LGE PSIR sequence. (c.1–3) Short axis views at basal (c.1), mid (c.2), and apical (c.3) levels, and long-axis views in four-chambers (c.4) and three-chambers (c.5). The arrows in these images show areas of focal fibrosis as midventricular LGE of the anteroseptal and inferior segments in (c.1) and in the subepicardium of the inferior segment in (c.2,3). (c.1) Shows mild pericardial effusion (asterisks) and minimal pericardial thickening (arrow), suggesting minimal pericardial inflammation. CMR, cardiovascular magnetic resonance; DS, DRESS syndrome; SSFP, steady-state free precession; LVEF%, left ventricular ejection fraction; RVEF%, right ventricular ejection fraction; T2-W STIR, T2-weighted short-tau inversion recovery; LGE, late gadolinium enhancement; PSIR, phase-sensitive inversion recovery.

derived from LGE imaging. The extracellular volume maps to detect, locate and quantify the myocardial fibrosis even if it is still not visible to the eyeball. The detection of fibrosis in PH is associated with poor prognosis (147, 267).

A recent meta-analysis of PH confirmed CMR as a powerful prognostic marker in PH, confirming that RV function and RV and LV volumes predict mortality and that RV volumes and function predict clinical worsening and poor response to medical treatment. Therefore, significant scientific evidence strongly supports the proposal of considering CMR as part of the diagnostic algorithm in AD (267).

CMR promises the accuracy, precision, and reproducibility required in this group of patients because of its non-invasive, non-radiation linked assessment of myocardial tissue characterization by conventional and novel multiparametric methods, the gold standard in biventricular function and volumes assessment, and ability to assess microvascular dysfunction. CMR is also excellent in evaluating valves, thrombosis, and conduction-linked myocardial disorders, besides pericardial, vascular, and aortic involvements linked to ADs.

Recent advances in CMR, including broad availability, less operator dependence, faster sequences, and cost-effectiveness (101), support its value in early and accurate detection and differentiation of myocardial damage, even in preserved cardiac wall motion and cavity size. CMR in ADs provides relevant information to ensure early diagnosis and timely treatment of these high-risk patients. Despite the clear valuable role of CMR in ADs, there are still gaps in strategies and recommendations in health and intervention policy approaches for patients with ADs with CVD, requiring extensive, in-depth, multicenter clinical trials, establishing the imperative need to use CMR imaging as a non-invasive diagnostic modality of choice relevant to detect pathology in patients with multisystem autoimmune conditions.

Cardiac involvement in all mentioned ADs is there, waiting to be correctly and optimally discovered with current state-of-the-art imaging modalities. Using the proper imaging technique

| Pathophysiology | CMR offer | Sequences |
|-----------------|-----------|-----------|
| LV dysfunction  | The gold standard for LV function | Cine—SSFP |
| Myocarditis      | Identification and quantification. Follow up free of radiation. | T2-W-STIR, T1, T2-mapping, ECV LGE-PSIR |
| Pericarditis     | Identification. Measurement of pericardial thickness. Detection of inflammation. Detection of constriction. Follow up free of radiation. | Cine—SSFP, Free-breathing real-time cine T1-W, T2-W STIR LGE-PSIR |

SSFP: steady-state free precession; T2-W, T2-weighted; ECV, extracellular volume; T2W-STIR, T2-weighted short-tau inversion recovery; LGE, late gadolinium enhancement; PSIR, phase-sensitive inversion recovery.
at the precise moment will translate into earlier and better diagnosis, adequate treatment, appropriate follow-up, and less long-term morbidity and mortality.

Currently, it is in-press and European Association of Cardiovascular Imaging (EACVI) Position Paper, entitled Role of Cardiovascular Magnetic Resonance in Autoimmune Rheumatic Diseases, where Mavrogeni et al. (268) review the promising role of CMR in the early and accurate diagnosis of the CV involvement in the AD, providing comprehensive CMR protocols and diagnostic algorithms for its use, highlighting its role to start the precise and effective specific therapeutic approach timely and not when conventional imaging modalities and the clinical manifestations show the involvement of the CV system; impacting the outcomes of these complex patients positively.

Well-designed multicenter trials to broadly confirm the findings, pathophysiological meaning, and prognostic information are needed to include CMR as part of the clinical routine in the future guidelines for the AD.

**AUTHOR CONTRIBUTIONS**

LS-G, MB, AA-D, JM-S, CS, BS, EM, and MS-L outlined, drafted, and contributed to the writing of the manuscript. All authors approved the final version of the manuscript.

**ACKNOWLEDGMENTS**

The authors want to recognize Ana Camila Flores-Ventura for her kind assistance in post-processing some images.

**REFERENCES**

1. Friedrich MG, Bucciarelli-Ducci C, White JA, Plein S, Moon JC, Almeida AG, et al. Simplifying cardiovascular magnetic resonance pulse sequence terminology. *J Cardiovasc Magn Reson.* (2014) 16:3960. doi: 10.1186/s12968-014-0103-z

2. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, et al. ACCF/ACR/AHA/NASCRI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance. A Report of the American College of Cardiology foundation task force on expert consensus documents. *J Am Coll Cardiol.* (2010) 55:2614–62. doi: 10.1016/j.jacc.2009.11.011

3. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. *J Am Coll Cardiol.* (2022) 79:e263–421. doi: 10.1016/j.jacc.2021.12.012

4. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* (2021) 43:561–632. doi: 10.1093/eurheartj/ehac051

5. Visseren FJJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with the special contribution of the European Society of Cardiology and 12 medical societies with. *Eur Heart J.* (2021) 42:3227–337. doi: 10.1093/eurheartj/ehab484

6. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. Corrigendum to: 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. *Eur Heart J.* (2022) 24:699. doi: 10.1093/eurheartj/ehac023

7. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) with the special contribution of the European Heart. *Eur Heart J.* (2021) 42:3427–520. doi: 10.1093/eurheartj/ehab699

8. McDonald TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution. *Eur Heart J.* (2021) 42:3599–726. doi: 10.1093/eurheartj/ehab368

9. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* (2018) 72:e91–220. doi: 10.1016/j.jacc.2017.10.054

10. Amsterdam EA, Wenger NK, Brindis RG, Casey DEJ, Ganiats TG, Holmes DRJ, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. *J Am Coll Cardiol.* (2014) 64:e139–228. doi: 10.1016/CIR.000000000000133

11. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHES/SCAI/SIR/SCCM/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol United States.* (2021) 78:1879–285. doi: 10.1016/CIR.000000000001029

12. Ibáñez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology. *Eur Heart J.* (2018) 39:119–77. doi: 10.1093/eurheartj/ehx293

13. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J.* (2020) 41:407–77. doi: 10.1093/eurheartj/ehz425

14. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm. *J Am Coll Cardiol.* (2019) 74:e51–156. doi: 10.1016/j.jacc.2018.10.044

15. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* (2020). 76:e159–240. doi: 10.1016/j.jacc.2020.08.045

16. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin 3rd JP, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* (2021). 77:e25–197. doi: 10.1016/CIR.000000000000923

17. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cifkova R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J.* (2018) 39:3165–241. doi: 10.1093/eurheartj/ehy478
patients at increased risk for cardiovascular events. J Hypertens. (2011) 29:565–73. doi: 10.1097/HJH.0b013e328342188

128. Cioffi G, Russo TE, Selmi A, Stefenni C, Furlanello F. Analysis of left ventricular systolic function by midwall mechanics in patients with obstructive sleep apnea. Eur J Echocardiogr Work Gr Echocardiogr Eur Soc Cardiol. (2011) 12:61–8. doi: 10.1093/ejechocard/jer106

129. Bartoloni E, Angeli F, Marcucci E, Perricone C, Cafaro G, Riccini C, et al. Unattended compared to traditional blood pressure measurement in patients with rheumatoid arthritis: a randomised cross-over study. Ann Med. (2021) 53:2050–9. doi: 10.1007/s00028-021-1999493

130. Badui E, Jiménez I, Saldivar C, Mintz G, Lavelle C, Fraga A. The heart and rheumatoid arthritis. Prospective study of 100 cases. Arch Int Cardiol Mex. (1987) 57:159–67.

131. Cioffi G, Paggiano P, Vizzardi E, Tarantini L, Cramariuc D, Gerdtz E, et al. Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. Heart. (2011) 97:301–7. doi: 10.1136/hrt.2010.192997

132. Kearney LG, Lu K, Ord M, Patel SK, Profitis K, Matalanis G, et al. Global longitudinal strain is a strong independent predictor of all-cause mortality in patients with aortic stenosis. Eur Heart J Cardiovasc Imaging. (2012) 13:827–33. doi: 10.1093/ehjci/jes115

133. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Dhillon MS, et al. Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Ann Rheum Dis. (2009) 68:1878–84. doi: 10.1136/ard.2008.094151

134. Nicola PJ, Crowson CS, Maradit-Kremers H, Ballman K V, Roger VL, Jacobsen SJ, et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum. (2006) 54:640–7. doi: 10.1002/art.21560

135. Myasoedova E, Davis JM, 3rd, Crowson CS, Roger VL, Karln BL, Borgesen DD, et al. Brief report: rheumatoid arthritis is associated with left ventricular concentric remodeling: results of a population-based cross-sectional study. Arthritis Rheum. (2013) 65:1713–8. doi: 10.1002/art.37949

136. Rudomine RL, Roman MJ, Devereux RB, Paget SA, Schwartz JE, Lockshin MD, et al. Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum. (2009) 60:22–9. doi: 10.1002/art.24148

137. Giles JT, Malayeri AA, Fernandes V, Post W, Blumenthal RS, Bluemke DA, et al. Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. Chin Med J. (2021) 71. doi: 10.1097/CM9.0000000000005355
219. Lau EW, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody. *Arthritis Rheum.* (1980) 23:881–8. doi: 10.1002/art.1780230802

220. Zamarrón-de Lucas E, Cómez-Carrera L, Bonilla G, Petit D, Manguas A, Álvarez-Sala R. Antisynthetase syndrome: analysis of 11 cases. *Med Clin.* (2017) 148:166–9. doi: 10.1016/j.medcle.2017.02.018

221. Tanboon J, Inoue M, Hirakawa S, Tachimori H, Hayashi S, Noguchi S, et al. Pathologic features of anti-mi-2 dermatomyositis. *Neurology.* (2021) 96:e448–59. doi: 10.1212/WN1.0000000011269

222. Bories E, Fortenfant F, Pugnet G, Renaudineau Y, Bost C. Myositis-specific autoantibodies in clinical practice: improving the performance of the immunodot. *Semin Arthritis Rheum.* (2022) 55:151998. doi: 10.1016/s0049-0172(20)31998-4

223. Walcher T, Steinbach P, Spiess J, Kunze M, Gradinger R, Walcher D, et al. Detection of long-term progression of myocardial fibrosis in Duchenne muscular dystrophy in an affected family: a cardiovascular magnetic resonance study. *Eur J Radiol.* (2011) 80:115–9. doi: 10.1016/j.ejrad.2010.07.005

224. Puchalski MD, Williams R V, Askovich B, Sower CT, Hor KH, Su JT, et al. Unusual cause of spontaneous atraumatic intra-pericardial thrombosis. *J Am Coll Cardiol.* (2009) 2:6564. doi: 10.4076/1757-1626-2-6564

225. Neumann T, Manger B, Schmid M, Kroegel C, Hansch A, Kaiser J. Severe biventricular thrombosis in eosinophilic granulomatosis with polyangiitis: a case report. *Med Clin.* (2017) 148:166–9. doi: 10.1016/j.medcle.2017.02.018

226. Hasley PB, Dollansbee WP, Coulehan JL. Cardiac manifestations of Churg-Strauss syndrome: report of a case and review of the literature. *Am Heart J.* (1990) 129:996–9. doi: 10.1016/0002-8703(90)90227-O

227. Francis W, Aziz E, Al Kuwari MA, Ghareep A-N, Peyrou J, Szumielski W. A rare right ventricular involvement of eosinophilic granulomatosis demonstrated by cardiac MRI. *Polish J Radiol.* (2016) 81:598–601. doi: 10.26597/PJR.899864

228. Akerøy L, Amundsen BH, Skomsøvill JF, Haugen BO, Soma J, 50-year-old man with eosinophilia and cardiomyopathy: need for endomyocardial biopsy? *Eur J Echocardiogr* J Work Gr Echocardiogr Eur Soc Cardiol. (2011) 12:257–9. doi: 10.1093/ejehocard/qej167

229. Gill JS, Fontana M, Knight D, Kalra S. A case report of eosinophilic granulomatosis and polyangiitis myocarditis presenting as ST elevation myocardial infarction and showing positive response to immunotherapy. *Eur J Heart J* (2019) 31:3–6. doi: 10.1093/eurheartj/etx161

230. Neumann T, Manger B, Schmid M, Kroegel C, Hansch A, Kaiser J. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. *Medicine (Baltimore).* (2009) 88:236–43. doi: 10.1097/MD.0b013e3181535a5

231. Guillemin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Cardiac involvement in Churg-Strauss syndrome: prospective evaluation of a tertiary referral centre. *Eur J Intern Med.* (2020) 85:68–79. doi: 10.1016/j.ejim.2020.12.008

232. Hamudi J, Karkabi B, Zisman D, Shiran A. Severe biventricular thrombosis in eosinophilic granulomatosis with polyangiitis: a case report. *Eur J Heart J Case Rep.* (2020) 4:1–5. doi: 10.1093/eurjhr/ejy141

233. Neumann T, Manger B, Schmid M, Kroegel C, Hansch A, Kaiser WA, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. *Diagnostics.* (2019) 9:26. doi: 10.3390/diagnostics9030026

234. Wagner AD, Meyer GP, Rihl M, Rathmann A, Wittkop U, Zeidler H, et al. Cardiac involvement of Churg-Strauss syndrome as a reversible cause of dilated cardiomyopathy. *Heart.* (2015) 101:33–4. doi: 10.1136/heartjnl-2014-306590

235. Ziegler H, Al Tansui A, Al Nuaimi I, Al Nuaimi M. Coronary artery vasospasm in a patient with Churg-Strauss syndrome. *BMJ Case Rep.* (2018) 2018:bcr2018225321. doi: 10.1136/bcr-2018-225321

236. Petrapkopoulos P, Franz WM, Boeksteegers P, Weiss M. Vasoactive angina pectoris associated with Churg-Strauss syndrome. *Nat Clin Pract Cardiovasc Med.* (2005) 2:484–9; quiz 490. doi: 10.1038/ncpcardio0299

237. Drouge M, Vergnon JM, Wintzer B, Antoine JC, Malquarti V, Prinzmetal’s angina pectoris revealing aneurysm of the right coronary artery during evolution of Churg-Strauss syndrome. *Chest.* (1993) 103:978–84. doi: 10.1378/chest.103.3.978a

238. Wagner AD, Meyer GP, Rihl M, Rathmann A, Wittkop U, Zeidler H, et al. Acute coronary syndrome associated with Churg-Strauss syndrome. *Vasc Health Risk Manag.* (2007) 3:775–9.

239. Okumura K, Yasue H, Matsuyma K, Ogawa H, Kugiyama K, Ishizaka H, et al. Diffuse disorder of coronary artery vasomotility in patients with coronary spastic angina. Hyperreactivity to the constrictor effects of acetylcholine and the dilator effects of nitroglycerin. *J Am Coll Cardiol.* (1996) 23:47–52. doi: 10.1016/0735-1097(95)00432-7

240. Kajiha H, Kato Y, Takasaki A, Nakagawa H, Tahara E, Otsuki T, et al. Periarthritis of coronary arteries with severe eosinophilic infiltration. A new pathologic entity (eosinophilic periarthritis)? *Pathol Res Pract.* (1988) 184:46–52. doi: 10.1036/S0354-0338(88)01890-0

241. Wong CW, Luis S, Zeng I, Stewart RAH. Eosinophilia and coronary artery vasospasm. *Heart Lung Circ.* (2008) 17:488–96. doi: 10.1016/j.hlc.2008.06.003

242. Zagelidou H, Leodari R, Roupa Z, Maras D, Sapountzi-Krepia D, Terzis A. Death from spontaneous coronary artery dissection in a healthy postmenopausal woman. *Am J Forensic Med Pathol.* (2004) 25:176–7. doi: 10.1097/00000438-200407-05

243. Kubota T, Yamagishi M, Higashihara M, Sakamoto H, Ishikawa T, et al. Survivor of cardiogenic shock following acute myocardial infarction with Churg-Strauss syndrome: first angiographic documentation of coronary recanalization of infarct-related arteries: a case report. *J Cardiol.* (2004) 44:153–9.

244. Allenbach Y, Seror R, Pagnoux C, Teixeira L, Gulpain P, Guileville L. High frequency of venous thromboembolic events in Churg-Strauss syndrome,
Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. *Ann Rheum Dis.* (2009) 68:564–7. doi: 10.1136/ard.2008.099051

Garcia-Vives E, Rodriguez-Palomares JE, Harty L, Solano-Laque R, Jayne D. Heart disease in eosinophilic granulomatosis with polyangiitis (EGPA) patients: a screening approach: proposal. *Rheumatology.* (2021) 60:4538–47. doi: 10.1093/rheumatology/keab027

Maria A, Guiplain P, Forestier A, Delhom E, Schifff A, Rivièrè S, et al. Asymptomatic bilateral pulmonary embolism in Churg-Strauss syndrome. *Eur Respir Rev.* (2012) 21:75 LP–77. doi: 10.1183/09059180.00007911

Ames PR, Margaglione M, Mackie S, Alves JD. Eosinophilia and thrombophilia in Churg-Strauss syndrome: a clinical and pathogenetic overview. *Clin Appl Thromb Off J Int Acad Clin Appl Thromb.* (2010) 16:628–36. doi: 10.1177/1076289009348647

Ames PR, Roes L, Lupoli S, Pickering M, Brancacci V, Khamashta MA, et al. Thrombosis in Churg-Strauss syndrome. *Beyond vasculitis? Br J Rheumatol.* (1996) 35:1181–3. doi: 10.1093/rheumatology/35.11.1181

Wang J-G, Mahmud SA, Thompson JA, Geng J-G, Key NS, Slungaard AA. DRESS syndrome: a late sequela of DRESS: two cases. *J Acad Dermatol.* (2011) 68:301–8. doi: 10.1016/j.jaad.2010.12.013

Thongsi T, Chulorajanamontri L, Pichler WJ. Cardiac involvement in DRESS syndrome. *Asian Pacific J Allergy Immunol.* (2017) 35:3–10. doi: 10.12932/AP0847

Morikawa D, Hiraoka E, Obunai K, Norisue Y. Myocarditis associated with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a case report and review of the literature. *Am J Case Rep.* (2018) 19:978–84. doi: 10.12659/ AJCR.990569

Callot V, Roujeau JC, Bagot M, Wechsler J, Chosidow O, Souteyrand P, et al. Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. *Arch Dermatol.* (1996) 132:1315–21. doi: 10.1001/archderm.132.11.1315

Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). *Semina Gatan Med Surg.* (1996) 15:250–7. doi: 10.1016/S1085-5629(96)80038-1

Bourgeois GP, Cafardi JA, Grysman V, Pamboukian S V, Kirklin JK, Andea AA, et al. Fulminant myocarditis as a late sequela of DRESS: two cases. *J Acad Dermatol.* (2011) 65:889–90. doi: 10.1016/j.jaad.2010.12.013

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.